These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38640447)

  • 1. Developing Dry Powder Inhaler Formulations.
    Morton DAV; Barling D
    J Aerosol Med Pulm Drug Deliv; 2024 Apr; 37(2):90-99. PubMed ID: 38640447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical stability of dry powder inhaler formulations.
    Shetty N; Cipolla D; Park H; Zhou QT
    Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
    Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
    Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
    Lin YW; Wong J; Qu L; Chan HK; Zhou QT
    Curr Pharm Des; 2015; 21(27):3902-16. PubMed ID: 26290193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantitative approach to predicting lung deposition profiles of pharmaceutical powder aerosols.
    Yaqoubi S; Chan HK; Nokhodchi A; Dastmalchi S; Alizadeh AA; Barzegar-Jalali M; Adibkia K; Hamishehkar H
    Int J Pharm; 2021 Jun; 602():120568. PubMed ID: 33812969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation of Biopharmaceutical Dry Powder Inhaler Using the Void Forming Index (VFI) to Detect and Avoid Powder Caking in Dry Powder Inhaler Formulations.
    Maruyama S; Miyajima M; Yonemochi E
    Chem Pharm Bull (Tokyo); 2022; 70(4):245-253. PubMed ID: 35370200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in lactose blend formulations for carrier-based dry powder inhalation.
    Hebbink GA; Jaspers M; Peters HJW; Dickhoff BHJ
    Adv Drug Deliv Rev; 2022 Oct; 189():114527. PubMed ID: 36070848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supercritical Fluid Particle Design of DPI Formulations (Review).
    Sun Y
    Curr Pharm Des; 2015; 21(19):2516-42. PubMed ID: 25876911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
    Li J; Ma S; He X; Sun Y; Zhang X; Guan J; Mao S
    Int J Pharm; 2023 Jul; 642():123179. PubMed ID: 37364785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of void forming index (VFI): Detection of the effect of physical properties of dry powder inhaler formulations on powder cohesion.
    Maruyama S; Ando S; Yonemochi E
    Int J Pharm; 2020 Oct; 588():119766. PubMed ID: 32800937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powder inhaler formulation comparison: Study of the role of particle deposition pattern and dissolution.
    Noriega-Fernandes B; Malmlöf M; Nowenwik M; Gerde P; Corvo ML; Costa E
    Int J Pharm; 2021 Sep; 607():121025. PubMed ID: 34418472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder Formulations.
    Boc S; Momin MAM; Farkas DR; Longest W; Hindle M
    AAPS PharmSciTech; 2021 Apr; 22(4):135. PubMed ID: 33860378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of Dry Powders to the Lungs: Influence of Particle Attributes from a Biological and Technological Point of View.
    Zellnitz S; Roblegg E; Pinto J; Fröhlich E
    Curr Drug Deliv; 2019; 16(3):180-194. PubMed ID: 30360739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.